Antiasthmatic prescriptions in children with and without congenital anomalies: a population-based study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Antiasthmatic prescriptions in children with and without congenital anomalies : a population-based study. / Divin, Natalie; Given, Joanne Emma; Tan, Joachim; Astolfi, Gianni; Ballardini, Elisa; Barrachina-Bonet, Laia; Cavero-Carbonell, Clara; Coi, Alessio; Garne, Ester; Gissler, Mika; Heino, Anna; Jordan, Susan; Pierini, Anna; Scanlon, Ieuan; Urhøj, Stine Kjær; Morris, Joan K; Loane, Maria.
In: BMJ Open, Vol. 13, No. 10, e068885, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antiasthmatic prescriptions in children with and without congenital anomalies
T2 - a population-based study
AU - Divin, Natalie
AU - Given, Joanne Emma
AU - Tan, Joachim
AU - Astolfi, Gianni
AU - Ballardini, Elisa
AU - Barrachina-Bonet, Laia
AU - Cavero-Carbonell, Clara
AU - Coi, Alessio
AU - Garne, Ester
AU - Gissler, Mika
AU - Heino, Anna
AU - Jordan, Susan
AU - Pierini, Anna
AU - Scanlon, Ieuan
AU - Urhøj, Stine Kjær
AU - Morris, Joan K
AU - Loane, Maria
N1 - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023
Y1 - 2023
N2 - OBJECTIVES: To explore the risk of being prescribed/dispensed medications for respiratory symptoms and breathing difficulties in children with and without congenital anomalies.DESIGN: A EUROlinkCAT population-based data linkage cohort study. Data on children with and without congenital anomalies were linked to prescription databases to identify children who did/did not receive antiasthmatic prescriptions. Data were analysed by age, European region, class of antiasthmatic, anomaly, sex, gestational age and birth cohort.SETTING: Children born 2000-2014 in six regions within five European countries.PARTICIPANTS: 60 662 children with congenital anomalies and 1 722 912 reference children up to age 10 years.PRIMARY OUTCOME MEASURE: Relative risks (RR) of >1 antiasthmatic prescription in a year, identified using Anatomical Therapeutic Chemical classification codes beginning with R03.RESULTS: There were significant differences in the prescribing of antiasthmatics in the six regions. Children with congenital anomalies had a significantly higher risk of being prescribed antiasthmatics (RR 1.41, 95% CI 1.35 to 1.48) compared with reference children. The increased risk was consistent across all regions and all age groups. Children with congenital anomalies were more likely to be prescribed beta-2 agonists (RR 1.71, 95% CI 1.60 to 1.83) and inhaled corticosteroids (RR 1.74, 95% CI 1.61 to 1.87). Children with oesophageal atresia, genetic syndromes and chromosomal anomalies had over twice the risk of being prescribed antiasthmatics compared with reference children. Children with congenital anomalies born <32 weeks gestational age were over twice as likely to be prescribed antiasthmatics than those born at term (RR 2.20, 95% CI 2.10 to 2.30).CONCLUSION: This study documents the additional burden of respiratory symptoms and breathing difficulties for children with congenital anomalies, particularly those born preterm, compared with children without congenital anomalies in the first 10 years of life. These findings are beneficial to clinicians and healthcare providers as they identify children with greater morbidity associated with respiratory symptoms, as indicated by antiasthmatic prescriptions.
AB - OBJECTIVES: To explore the risk of being prescribed/dispensed medications for respiratory symptoms and breathing difficulties in children with and without congenital anomalies.DESIGN: A EUROlinkCAT population-based data linkage cohort study. Data on children with and without congenital anomalies were linked to prescription databases to identify children who did/did not receive antiasthmatic prescriptions. Data were analysed by age, European region, class of antiasthmatic, anomaly, sex, gestational age and birth cohort.SETTING: Children born 2000-2014 in six regions within five European countries.PARTICIPANTS: 60 662 children with congenital anomalies and 1 722 912 reference children up to age 10 years.PRIMARY OUTCOME MEASURE: Relative risks (RR) of >1 antiasthmatic prescription in a year, identified using Anatomical Therapeutic Chemical classification codes beginning with R03.RESULTS: There were significant differences in the prescribing of antiasthmatics in the six regions. Children with congenital anomalies had a significantly higher risk of being prescribed antiasthmatics (RR 1.41, 95% CI 1.35 to 1.48) compared with reference children. The increased risk was consistent across all regions and all age groups. Children with congenital anomalies were more likely to be prescribed beta-2 agonists (RR 1.71, 95% CI 1.60 to 1.83) and inhaled corticosteroids (RR 1.74, 95% CI 1.61 to 1.87). Children with oesophageal atresia, genetic syndromes and chromosomal anomalies had over twice the risk of being prescribed antiasthmatics compared with reference children. Children with congenital anomalies born <32 weeks gestational age were over twice as likely to be prescribed antiasthmatics than those born at term (RR 2.20, 95% CI 2.10 to 2.30).CONCLUSION: This study documents the additional burden of respiratory symptoms and breathing difficulties for children with congenital anomalies, particularly those born preterm, compared with children without congenital anomalies in the first 10 years of life. These findings are beneficial to clinicians and healthcare providers as they identify children with greater morbidity associated with respiratory symptoms, as indicated by antiasthmatic prescriptions.
U2 - 10.1136/bmjopen-2022-068885
DO - 10.1136/bmjopen-2022-068885
M3 - Journal article
C2 - 37832979
VL - 13
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 10
M1 - e068885
ER -
ID: 369782919